Corline Biomedical - Public Comps and Valuation Multiples

Corline Biomedical Overview

About Corline Biomedical

Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.

Founded

1991

HQ

Employees

Website

corline.se

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $1.4M

LTM EBITDA -$0.8M

EV

$46.6M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Corline Biomedical Financials

As of November 2025, Corline Biomedical reported last 12-month revenue of $1.4M and EBITDA of -$0.8M.

In the same period, Corline Biomedical achieved -$0.9M in LTM net income.

See Corline Biomedical valuation multiples based on analyst estimates

Corline Biomedical P&L

In the most recent fiscal year, Corline Biomedical reported revenue of $1.0M and EBITDA of -$2.4M.

Corline Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Corline Biomedical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.4M	XXX	$1.0M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$1.4M	XXX	XXX	XXX
Gross Margin	n/a	XXX	138%	XXX	XXX	XXX
EBITDA	-$0.8M	XXX	-$2.4M	XXX	XXX	XXX
EBITDA Margin	-60%	XXX	-236%	XXX	XXX	XXX
EBIT	-$0.9M	XXX	-$1.4M	XXX	XXX	XXX
EBIT Margin	-67%	XXX	-135%	XXX	XXX	XXX
Net Profit	-$0.9M	XXX	-$2.5M	XXX	XXX	XXX
Net Margin	-67%	XXX	-237%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Corline Biomedical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.4M. EBITDA for the last twelve months was -$0.8M. In the most recent fiscal year, Corline Biomedical achieved $1.0M in revenue and -$2.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.4M	Analyst estimates available to subscribers	$1.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$1.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	137.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$0.8M	Analyst estimates available to subscribers	-$2.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-59.9% EBITDA margin	Analyst estimates available to subscribers	-236.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$0.9M	Analyst estimates available to subscribers	-$1.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-66.6% EBIT margin	Analyst estimates available to subscribers	-134.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$0.9M	Analyst estimates available to subscribers	-$2.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-66.6% net profit margin	Analyst estimates available to subscribers	-237.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Corline Biomedical

This financial data table provides comprehensive performance metrics for Corline Biomedical, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Corline Biomedical generated $1.4M in revenue over the last twelve months.
The company achieved -$0.8M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$0.9M.

Fiscal Year Performance

In the most recent fiscal year, Corline Biomedical reported $1.0M in total revenue.
Fiscal year EBITDA was -$2.4M.
The company maintained a gross profit margin of 137.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was -236.0%.
Net profit margin reached -237.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Corline Biomedical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Corline Biomedical Stock Performance

Corline Biomedical has current market cap of SEK 446M (or $47.2M), and EV of SEK 440M (or $46.6M).

Market Cap Evolution

Corline Biomedical Stock Data

As of December 3, 2025, Corline Biomedical's stock price is SEK 18 (or $2).

See Corline Biomedical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$46.6M	$47.2M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Corline Biomedical Valuation Multiples

Corline Biomedical's trades at 45.0x EV/Revenue multiple, and -19.1x EV/EBITDA.

See valuation multiples for Corline Biomedical and 15K+ public comps

Corline Biomedical Financial Valuation Multiples

As of December 3, 2025, Corline Biomedical has market cap of $47.2M and EV of $46.6M.

Equity research analysts estimate Corline Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Corline Biomedical has a P/E ratio of -51.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$47.2M	XXX	$47.2M	XXX	XXX	XXX
EV (current)	$46.6M	XXX	$46.6M	XXX	XXX	XXX
EV/Revenue	34.0x	XXX	45.0x	XXX	XXX	XXX
EV/EBITDA	-56.8x	XXX	-19.1x	XXX	XXX	XXX
EV/EBIT	-51.1x	XXX	-33.4x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-51.8x	XXX	-19.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-27.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Corline Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Corline Biomedical Margins & Growth Rates

Corline Biomedical's last 12 month revenue growth is 300%

Corline Biomedical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Corline Biomedical's rule of 40 is 293% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Corline Biomedical's rule of X is 689% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Corline Biomedical and other 15K+ public comps

Corline Biomedical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	300%	XXX	137%	XXX	XXX	XXX
EBITDA Margin	-60%	XXX	-236%	XXX	XXX	XXX
EBITDA Growth	-412%	XXX	n/a	XXX	XXX	XXX
Rule of 40	293%	XXX	64%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	689%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	272%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial